4.7 Article

The Clathrin-dependent Spindle Proteome

Journal

MOLECULAR & CELLULAR PROTEOMICS
Volume 15, Issue 8, Pages 2537-2553

Publisher

AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
DOI: 10.1074/mcp.M115.054809

Keywords

-

Funding

  1. National Health and Medical Research Council (NH&MRC) of Australia [APP1022218]
  2. NHMRC [477104, APP1069264]

Ask authors/readers for more resources

The mitotic spindle is required for chromosome congression and subsequent equal segregation of sister chromatids. These processes involve a complex network of signaling molecules located at the spindle. The endocytic protein, clathrin, has a moonlighting role during mitosis, whereby it stabilizes the mitotic spindle. The signaling pathways that clathrin participates in to achieve mitotic spindle stability are unknown. Here, we assessed the mitotic spindle proteome and phosphoproteome in clathrin-depleted cells using quantitative MS/MS (data are available via ProteomeXchange with identifier PXD001603). We report a spindle proteome that consists of 3046 proteins and a spindle phosphoproteome consisting of 5157 phosphosites in 1641 phosphoproteins. Of these, 2908 (95.4%) proteins and 1636 (99.7%) phosphoproteins are known or predicted spindle-associated proteins. Clathrin-depletion from spindles resulted in dysregulation of 121 proteins and perturbed signaling to 47 phosphosites. The majority of these proteins increased in mitotic spindle abundance and six of these were validated by immunofluorescence microscopy. Functional pathway analysis confirmed the reported role of clathrin in mitotic spindle stabilization for chromosome alignment and highlighted possible new mechanisms of clathrin action. The data also revealed a novel second mitotic role for clathrin in bipolar spindle formation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Targeting Glioma Stem Cells by Functional Inhibition of Dynamin 2: A Novel Treatment Strategy for Glioblastoma

Rodney Luwor, Andrew P. Morokoff, Stephanie Amiridis, Giovanna D'Abaco, Lucia Paradiso, Stanley S. Stylli, Hong P. T. Nguyen, Mark Tarleton, Kelly A. Young, Terence J. O'Brien, Phillip J. Robinson, Megan Chircop, Adam McCluskey, Nigel C. Jones

CANCER INVESTIGATION (2019)

Article Chemistry, Multidisciplinary

A Direct Fluorescent Activity Assay for Glycosyltransferases Enables Convenient High-Throughput Screening: Application to O-GlcNAc Transferase

Matthew G. Alteen, Christina Gros, Richard W. Meek, David A. Cardoso, Jil A. Busmann, Gontran Sangouard, Matthew C. Deen, Hong-Yee Tan, David L. Shen, Cecilia C. Russell, Gideon J. Davies, Phillip J. Robinson, Adam McCluskey, David J. Vocadlo

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2020)

Article Biochemistry & Molecular Biology

Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies

Hui Yi Chew, Priscila O. De Lima, Jazmina L. Gonzalez Cruz, Blerida Banushi, Godwins Echejoh, Lingbo Hu, Shannon R. Joseph, Benedict Lum, James Rae, Jake S. O'Donnell, Lilia Merida de Long, Satomi Okano, Brigid King, Rachael Barry, Davide Moi, Roberta Mazzieri, Ranjeny Thomas, Fernando Souza-Fonseca-Guimaraes, Matthew Foote, Adam McCluskey, Phillip J. Robinson, Ian H. Frazer, Nicholas A. Saunders, Robert G. Parton, Riccardo Dolcetti, Katharine Cuff, Jennifer H. Martin, Benedict Panizza, Euan Walpole, James W. Wells, Fiona Simpson

Article Multidisciplinary Sciences

Strategies to enable large-scale proteomics for reproducible research

Rebecca C. Poulos, Peter G. Hains, Rohan Shah, Natasha Lucas, Dylan Xavier, Srikanth S. Manda, Asim Anees, Jennifer M. S. Koh, Sadia Mahboob, Max Wittman, Steven G. Williams, Erin K. Sykes, Michael Hecker, Michael Dausmann, Merridee A. Wouters, Keith Ashman, Jean Yang, Peter J. Wild, Anna deFazio, Rosemary L. Balleine, Brett Tully, Ruedi Aebersold, Terence P. Speed, Yansheng Liu, Roger R. Reddel, Phillip J. Robinson, Qing Zhong

NATURE COMMUNICATIONS (2020)

Article Multidisciplinary Sciences

Small molecule inhibition of Dynamin-dependent endocytosis targets multiple niche signals and impairs leukemia stem cells

Cedric S. Tremblay, Sung Kai Chiu, Jesslyn Saw, Hannah McCalmont, Veronique Litalien, Jacqueline Boyle, Stefan E. Sonderegger, Ngoc Chau, Kathryn Evans, Loretta Cerruti, Jessica M. Salmon, Adam McCluskey, Richard B. Lock, Phillip J. Robinson, Stephen M. Jane, David J. Curtis

NATURE COMMUNICATIONS (2020)

Correction Multidisciplinary Sciences

Small molecule inhibition of Dynamin-dependent endocytosis targets multiple niche signals and impairs leukemia stem cells (vol 11, 6211, 2020)

Cedric S. Tremblay, Sung Kai Chiu, Jesslyn Saw, Hannah McCalmont, Veronique Litalien, Jacqueline Boyle, Stefan E. Sonderegger, Ngoc Chau, Kathryn Evans, Loretta Cerruti, Jessica M. Salmon, Adam McCluskey, Richard B. Lock, Phillip J. Robinson, Stephen M. Jane, David J. Curtis

NATURE COMMUNICATIONS (2021)

Review Hematology

Shutting the gate: targeting endocytosis in acute leukemia

Cedric S. Tremblay, Stephen B. Ting, Adam McCluskey, Phillip J. Robinson, David J. Curtis

Summary: Endocytosis plays a crucial role in controlling cellular processes and cellular responses to the microenvironment. Targeting therapeutic strategies based on endocytosis show promise for the treatment of hematological malignancies.

EXPERIMENTAL HEMATOLOGY (2021)

Article Chemistry, Medicinal

Pyrimidyn-Based Dynamin Inhibitors as Novel Cytotoxic Agents

Luke R. Odell, Ngoc Chau, Cecilia C. Russell, Kelly A. Young, Jayne Gilbert, Phillip J. Robinson, Jennette A. Sakoff, Adam McCluskey

Summary: The study involved the synthesis of pyrimidine-based dynamin GTPase inhibitors, with di- and tri-substituted pyrimidines showing higher levels of dynamin inhibition and potentially stronger cytotoxicity. These inhibitors demonstrated a good correlation between dynamin inhibition and cytotoxicity in various cancer cell lines.

CHEMMEDCHEM (2022)

Article Biochemical Research Methods

Proteomic profiling of idiopathic Parkinson's disease primary patient cells by SWATH-MS

Stephen A. Wood, Peter G. Hains, Arnaud Muller, Melissa Hill, Susitha Premarathne, Mariyam Murtaza, Phillip J. Robinson, George D. Mellick, Alex M. Sykes

Summary: In this study, we quantified proteomic differences between healthy control and PD patient cells and identified the critical role of the unfolded protein response (UPR) in PD patients. PD patients with high amounts of PDIA6 and HYOU1 proteins were more sensitive to endoplasmic reticulum stress. These findings provide insight into underlying cellular dysfunctions in PD patients.

PROTEOMICS CLINICAL APPLICATIONS (2022)

Article Oncology

Pan-cancer proteomic map of 949 human cell lines

Emanuel Goncalves, Rebecca C. Poulos, Zhaoxiang Cai, Syd Barthorpe, Srikanth S. Manda, Natasha Lucas, Alexandra Beck, Daniel Bucio-Noble, Michael Dausmann, Caitlin Hall, Michael Hecker, Jennifer Koh, Howard Lightfoot, Sadia Mahboob, Iman Mali, James Morris, Laura Richardson, Akila J. Seneviratne, Rebecca Shepherd, Erin Sykes, Frances Thomas, Sara Valentini, Steven G. Williams, Yangxiu Wu, Dylan Xavier, Karen L. MacKenzie, Peter G. Hains, Brett Tully, Phillip J. Robinson, Qing Zhong, Mathew J. Garnett, Roger R. Reddel

Summary: The study analyzes the proteomes of multiple cancer cell lines through mass spectrometry and reveals thousands of cancer protein biomarkers that are not significant at the transcript level, demonstrating that the proteome has predictive power for drug response similar to the transcriptome.

CANCER CELL (2022)

Review Biochemical Research Methods

Clinical applications of mass spectrometry-based proteomics in cancer: Where are we?

Emma L. Boys, Jia Liu, Phillip J. Robinson, Roger R. Reddel

Summary: Tumor tissue processing methodologies combined with data-independent acquisition mass spectrometry (DIA-MS) can accurately analyze the proteome of multiple tumor samples, providing new insights into cancer classification, tumor biology, biomarkers, treatment response, and drug targets. However, these technologies have not yet been widely implemented in routine cancer clinical practice.

PROTEOMICS (2023)

Article Biochemical Research Methods

Opportunities for pharmacoproteomics in biomarker discovery

Rebecca C. Poulos, Zhaoxiang Cai, Phillip J. Robinson, Roger R. Reddel, Qing Zhong

Summary: Proteomic data are valuable for drug response prediction and biomarker discovery due to the direct interaction between most drugs and proteins in target cells. This review highlights the opportunities of combining large-scale proteomic data with drug-related research, focusing on oncology. Successful applications of drug response prediction using molecular data are discussed, along with the technical advances in data-independent acquisition mass spectrometry (DIA-MS) for biomarker discovery. The potential of machine learning in pharmacoproteomics and the challenges of clinical validation are also explored.

PROTEOMICS (2023)

Article Chemistry, Medicinal

Prodrugs of the Archetypal Dynamin Inhibitor Bis-T-22

Luke R. Odell, Mark J. Robertson, Kelly A. Young, Andrew B. McGeachie, Annie Quan, Phillip J. Robinson, Adam McCluskey

Summary: The Bis-T series of compounds are potent inhibitors of dynamin GTPase activity. However, their low cell permeability limits their activity. To overcome this, prodrug ester analogues were synthesized. Among them, propionic ester 4 showed the highest efficacy, as it could effectively cross the cell membrane and rapidly hydrolyze into the desired Bis-T-22.

CHEMMEDCHEM (2022)

Article Chemistry, Medicinal

Wiskostatin and other carbazole scaffolds as off target inhibitors of dynamin I GTPase activity and endocytosis

Peter J. Cossar, David Cardoso, Daniel Mathwin, Cecilia C. Russell, Beatrice Chiew, Michael P. Hamilton, Jennifer R. Baker, Kelly A. Young, Ngoc Chau, Phillip J. Robinson, Adam McCluskey

Summary: Wiskostatin is a specific and potent inhibitor of the N-WASP actin remodeling complex. It also inhibits dynamin GTPase activity and endocytosis.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2023)

Meeting Abstract Oncology

Examining EGFR-mediated PI3K/Akt pathway in combination therapy of cetuximab and dynamin inhibition

Hui Yi Chew, Benedict Panizza, Caroline Cooper, Riccardo Dolcetti, Jim Coward, Adam McCluskey, Phillip J. Robinson, James W. Wells, Fiona Simpson

MOLECULAR CANCER RESEARCH (2020)

No Data Available